Event in Progress:
Discover the latest content that has just been published on Research Tree
Agilent Technologies delivered a mixed result and failed to meet Wall Street expectations on the revenue front but delivered an earnings beat. It did demonstrate the strength and resilience of its business model through the expanded operating margins. The lower-than-expected revenue growth was due to the lockdowns and the fact that the company closed its operations in Shanghai. The largest market of Agilent, its pharma business grew by 13%. The momentum in the energy and chemical business contin
Companies: Agilent Technologies (A:NYSE)Agilent Technologies, Inc. (A:NYS)
Agilent ended the year 2021 on a highly positive note with a top-line of $6.32 billion and revenues growing by as much as $1 billion (around 15%). The management delivered a double-digit growth in each of its three business units and was also able to demonstrate margin expansion at the operating margin level of nearly 200 basis points. The company provided analytical informatics and instruments to a wide customer range along with consumables and related services that ensure strong revenue sticki
Agilent had a particularly strong 2021 with revenues growing by as much as $1 billion (nearly 15%). The company managed to show double-digit growth in each of its three business units and was also able to demonstrate margin expansion at the operating margin level of nearly 200 basis points. Agilent supplied analytical informatics and instruments to a wide customer range along with consumables and related services that ensure strong revenue stickiness. Interestingly, the company’s geography-wise
Agilent had another strong quarter to close out an exceptional 2021. At $6.32 billion for fiscal 2021, its revenues are over $1 billion higher than last year. The company continues on its path to being one of the leading providers of chromatography and mass spectrometry tools with wide applications in end markets such as healthcare, chemical, energy, food, and environmental technology. The company saw its full-year core growth is up 15%, on top of gaining 1% last year. Agilent’s performance has
Agilent Technologies delivered another outstanding quarter with a staggering 26% growth in the top-line. The company also witnessed a strong margin expansion with operating margin up 230 basis points to about 26% and the earnings per share rising by 41% on a year-on-year basis. Cell Analysis, Liquid Chromatography and Mass Spectrometry platforms continued to be a major growth driver and with the Life Sciences and Applied Markets Group alone delivering a 43% growth. Agilent has witnessed a more c
Agilent delivered another decent quarter with robust growth across all geographies and end-markets. The company witnessed a strong momentum across each of its segments i.e., Life Sciences & Applied Markets Group, Agilent Cross Lab Group, and Diagnostics and Genomics Group. Pharma as an industry has performed well over the past few quarters and there has been a strong demand for the company’s offerings in cell analysis, liquid chromatography and mass spectrometry. The Chinese market in particular
Companies: Agilent Technologies, Inc. (A:NYS)Agilent Technologies (A:NYSE)
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: VSC ABT ABBV AFMD A GOOGL AMGN AZN BCART BMY EKTAB EXAS GSK ILMN IPH ISRG IBAB JNJ MDXH MDG1 MDT MRK MYGN NSTG NOVN OCX PFE RAYB ROG SAN SGEN TMO TNG VCYT VNRX XNCR ECX IMM
goetzpartners securities Limited
Research Tree provides access to ongoing research coverage, media content and regulatory news on Agilent Technologies, Inc..
We currently have 0 research reports from 4
EKF has reported a strong H1, with revenues of £37.5m and double-digit growth in underlying non-Covid related business. Management reports it is trading in line with expectations for the full year and we make no change to our profit forecasts at this stage. New growth initiatives are proceeding to plan and should lead to accelerated core growth from FY23 onwards. We continue to see substantial upside on successful execution with the shares trading on an FY23 P/E of 13.1x and an EV/EBITDA of just
Companies: EKF Diagnostics Holdings plc
Singer Capital Markets
Kromek reported full-year results to 30 April that were in line with the trading update of 16 May. Record visibility over our FY 2023 revenue forecast of £18m (c.53% of which is already contracted and 37% “Awarded not Contracted”, with the balance from its normal monthly run rate) is a great start for FY 2023 on which the company can build further. We are leaving forecasts unchanged for the moment, despite additional contract wins, and expect to introduce FY 2024 forecasts at the time of its int
Companies: Kromek Group Plc
Kromek announced a £1.7m fundraise by way of the issue of convertible loan notes (8% coupon, 18-month conversion period at 15p per share), which will allow the company to minimise any potential supply-chain disruption to the delivery of contracts during the year. We make only minor changes to forecasts to reflect the additional interest (c.£0.1m) accrued, with adjusted pre-tax loss increasing to £5.0m. We leave our target valuation of £118m (27p) unchanged, with near-term catalysts (e.g. a secon
Companies: Omega Diagnostics Group PLC
Dish of the day
No joiners today.
No leavers today.
What’s cooking in the IPO kitchen?
Unigel Group, intends to join the Aquis Growth Market. Unigel Group is a pioneer in the field of thixotropic gels for the fibre optic cable industry. The Company is also a supplier of laminated steel tapes to the fibre optic cable industry in the US. Thixotropic gels and laminated steel tapes are essential components to the rapidly growing global fibre optic cable market. The Group export
Companies: SDI FUL PURP OSI IXI BSE BRSD ATM
Companies: TIDE EXR FTC KMK PEB RBG ETP
Smith & Nephew reported mostly in-line Q2 22 numbers, missing the top-line estimates (-0.6%) but beating on the trading profit (+0.5%), albeit marginally.
The Q2 performance was overshadowed by a 100bp margin downgrade for FY22 (-50bps Y-o-Y vs +50bps previously), which sent the stock ~9% lower in the session following the update. The reiteration of the top-line growth outlook of 4-5% was no help either.
We will cut our estimates, largely to reflect the soft margin guidance.
Companies: Smith & Nephew PLC
In Q2, Astra sustained its solid top-line momentum. Like in the past few quarters, this outperformance was again driven by higher COVID-19 business sales and solid growth in Diabetes drug Farxiga. Moreover, the recovering Oncology and much-needed green shoots in Rare Diseases were the icing on the cake. Although, profitability again came under the scanner but should improve in the coming quarters/years as the company completes its ‘growth phase’. Overall, a decent set of results and our positive
Companies: AstraZeneca PLC
Companies: SourceBio International Plc
Dish of the day
No joiners today.
Leavers: No leavers today.
What’s cooking in the IPO kitchen?**
Inteliqo Limited, intends to join the Aquis Growth Market. Inteliqo Limited provides sales, marketing and distribution services to technology product owners under long-term distribution agreements. The Company has agreed its first such agreement in respect of the Ipedia iQ product range. The iQ product is a smart translation earphone (earbuds) system which offers integrated real time speech
Companies: ARBB ARO ETX NAH RENE SYM THR
Belluscura has announced that it has entered into a Group Purchasing Organisation Product Supply Agreement with VGM Group which further expands its distribution network across the US.
Companies: Belluscura PLC
Companies: Argo Blockchain Plc (ARB:LON)Kromek Group Plc (KMK:LON)
For the year to 30 April 2022 Kromek reported results in line with the Trading Update of 16 May: revenue of £12.1m, +16.5%YoY, and an EBITDA (adj.) loss of £1.2m. We estimate revenue in the Advanced Imaging division grew 28% YoY to £4.6m, whilst the CBRN segment grew 1.5x to £5.4m.
Kromek reports that it expects growth to accelerate in both its core segments – security-related CBRN and advanced imaging – with the prospect of “a substantial year-on-year increase in revenue”. The CBRN segment in
Smith & Nephew’s growth acceleration and margin expansion in Q2 should continue in H215, more reflecting internal changes than improvements in market fundamentals. Its c 13% premium on 2015 P/E to its global ortho peers is supported by its brisker growth and strategic value.
Feature article: Utility regulation – Changes afoot - Patching up a tainted model
While the gas supply crisis – and its price implications – have dominated the UK price regulated sectors in recent months, other issues have arisen that have seriously tainted the price regulation system itself. Indeed, it is fair to ask whether it is ‘’fit for purpose’’.
Back in 1984, price regulation, via an unsophisticated RPI-x formula, was introduced to prevent the privatised British Telecom (BT) from abusin
Companies: VTA TRX FCSS IBT STX RECI PANR PCA OCI APP ARBB BBGI CLIG E7F0 FEV ICGT DNL FAS FJV CSN
Hardman & Co